Modality
ADC
MOA
CAR-T CD19
Target
GPRC5D
Pathway
Apoptosis
CTCLFTD
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
Aug 2021
→ Mar 2030
Phase 2Current
NCT08939900
225 pts·FTD
2022-11→2030-03·Recruiting
NCT04124094
2,314 pts·FTD
2021-08→TBD·Not yet recruiting
2,539 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-053.9y awayPh2 Data· FTD
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Not yet…
P2
Recruit…
Catalysts
Ph2 Data
2030-03-05 · 3.9y away
FTD
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08939900 | Phase 2 | FTD | Recruiting | 225 | OS |
| NCT04124094 | Phase 2 | FTD | Not yet recr... | 2314 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Datoglumide | AbbVie | Approved | CFTR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP |